Roth Capital Resumes GenVec (GNVC) at Buy; Novartis (NVS) Program Reinvigorates Excitement
Tweet Send to a Friend
Roth Capital restarts GenVec, Inc. (Nasdaq: GNVC) at Buy and $8 price target.
Analyst Joseph Pantginis, Ph.D., commented, GenVec ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst Joseph Pantginis, Ph.D., commented, GenVec ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
